甲磺酸萘莫司他对高出血风险血液净化患者的抗凝治疗效果分析  

Analysis of Anticoagulant Treatment Effect of Naphtholimus Mesylate on High Bleeding Risk Blood Purification Patients

作　　者：孙梦 那雪凝 冯婷婷 SUN Meng;NA Xuening;FENG Tingting(Hemodialysis Center,Jingmen People's Hospital,Jingmen 428000,Hubei,China;Nephrology Department,Jing-men People's Hospital,Jingmen 428000,Hubei,China)

机构地区：[1]荆门市人民医院血液透析中心,湖北荆门428000 [2]荆门市人民医院肾内科,湖北荆门428000

出　　处：《系统医学》2024年第15期91-94,共4页Systems Medicine

基　　金：荆门市科学技术研究与开发计划(2023YFYB005)。

摘　　要：目的 研究高出血风险血液净化患者应用甲磺酸萘莫司他抗凝的临床治疗效果。方法 非随机选取2023年7—12月荆门市人民医院收治的70例高出血风险血液净化患者为研究对象,并根据治疗方法分为对照组与观察组,各35例。对照组予4%枸橼酸钠抗凝,观察组予甲磺酸萘莫司他抗凝,比较两组相关实验室指标差异。结果 治疗前两组各项实验室指标比较,差异无统计学意义(P均>0.05)。治疗后观察组血浆凝血酶原时间、凝血酶时间与部分凝血活酶时间均相比对照组缩短,差异有统计学意义(P均<0.05);观察组管路与透析器凝血状况分级优于对照组,差异有统计学意义(P<0.05);观察组血液净化患者的滤器平均寿命较对照组更长,差异有统计学意义(P<0.05);观察组并发症发生率为5.71%(2/35),低于对照组的22.86%(8/35),差异有统计学意义(χ^(2)=4.200,P<0.05)。结论 甲磺酸萘莫司他可降低高危出血风险血液净化患者的出凝血风险,延长滤器寿命。Objective To study the anticoagulation effect of naproxat mesylate in patients with high blood risk blood purification.Methods seventy patients with high blood risk of blood purification admitted to Jingmen People′s Hospi-tal from July to December 2023 were non-randomly selected as the study objects,and were divided into control group and observation group according to treatment methods,with thirty-five cases in each group.The control group was given 4%sodium citrate for anticoagulation,and the observation group was given napathmostat mesylate for anticoagu-lation.Results Before treatment,there was no significant difference in laboratory indexes between the two groups(P>0.05).After treatment,plasma prothrombin time,thrombin time and partial thrombin time in observation group were shortened compared with control group,and the differences were statistically significant(all P<0.05).The classifica-tion of coagulation status of tubes and dialyzers in observation group was better than that in control group,the differ-ence was statistically significant(P<0.05).The average life of the filter in the observation group was longer than that in the control group,the difference was statistically significant(P<0.05).The complication rate of the observation group was 5.71%(2/35),which was lower than 22.86%(8/35)of the control group,and the difference was statistically signifi-cant(χ^(2)=4.200,P<0.05).Conclusion Naproxat mesylate can reduce the risk of blood clotting and prolong the life of filter in patients with high risk of bleeding.

关 键 词：血液净化 高出血风险 凝血功能 甲磺酸萘莫司他 枸橼酸钠 出血性并发症 

分 类 号：R969.3[医药卫生—药理学]